Electra Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Employees
- 11
- Market Cap
- -
Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Volunteers
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Electra Therapeutics Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT05556863
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
🇦🇹Medical University of Vienna, Vienna, Austria
Open-label Study of ELA026 in Participants with Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Phase 2
Active, not recruiting
- Conditions
- Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
- Interventions
- First Posted Date
- 2022-06-13
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Electra Therapeutics Inc.
- Target Recruit Count
- 156
- Registration Number
- NCT05416307
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
© Copyright 2025. All Rights Reserved by MedPath